From Treatment to Prevention: The Rise of Geroscience

Modern science is shifting its focus, from treating diseases to addressing the biological
mechanisms that cause them. This emerging discipline, known as geroscience, studies
how cellular processes such as inflammation, vascular degradation, and immune
decline drive chronic illness.

At the Royal National Academy of Medicine of Spain (RANME), researchers are leading
the development of the National Geroscience Strategy (2026–2030), aimed at
integrating molecular biology, AI, and clinical research into a framework.
Its objective is not only to extend life, but to extend functional life, the years lived in
health, autonomy, and productivity.

Why Geroscience Matters

Potential Benefits:

● Early Diagnostics: Epigenetic clocks, telomere testing, and immune profiling can
identify biological age long before symptoms appear.
● Preventive Therapies: Targeting core aging mechanisms may delay or prevent
multiple diseases simultaneously.
● Systemic Impact: Reducing age related decline could reshape healthcare costs

Cautions:

● Complex and evolving regulatory pathways for anti aging clinical trials.
● Ethical questions surrounding enhancement versus treatment.
● High data and infrastructure demands for longitudinal biological monitoring.

From Science to Strategy

As chronic disease costs rise, geroscience offers a solution: prevention at the molecular
level.
Integrating this science into clinical and policy frameworks requires collaboration across
academia, regulators, and the private sector.For governments and investors, the
challenge lies in aligning innovation incentives with public health objectives, this means
ensuring equitable access while maintaining scientific rigor and ethical oversight.

How TAMVER CONSULTING Supports Clients

At TAMVER CONSULTING, we assist institutions and organizations in integrating
geroscience into public health, research, and investment strategies.

Our services include:

● Policy Design: Aligning geroscience innovation with national health objectives.
● Cost-Benefit Analysis: Evaluating fiscal and social returns from early intervention
and aging prevention programs.
● Scientific Due Diligence: Assessing the evidence base and scalability of
emerging therapies and diagnostic technologies.

We help transform longevity science into a sustainable healthcare strategy, linking
molecular research with policy, economics, and long term system resilience.

Conclusion

Geroscience marks a paradigm shift, from reacting to disease to proactively extending
health. As nations adapt their health systems for aging populations, integrating the
biology of aging into policy, practice, and investment will be essential.
Those who act early will lead in shaping the next era of medicine: one defined not only
by longer life, but by longer vitality.